Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01735539
Other study ID # UNottingham F/3/2009
Secondary ID
Status Active, not recruiting
Phase N/A
First received November 22, 2012
Last updated January 16, 2014
Start date December 2011
Est. completion date January 2014

Study information

Verified date January 2014
Source University of Nottingham
Contact n/a
Is FDA regulated No
Health authority UK: University of Nottingham Medical School Research Ethics CommitteeUK: University of Nottingham HTA Compliance Group
Study type Interventional

Clinical Trial Summary

The investigators plan to measure changes in muscle protein metabolism in response to feeding, comparing between a single large essential amino acid (EAA) feed (the normal building blocks of protein) and the provision of the same dose in 4 smaller feeds at 45min intervals. The investigators will perform this study in healthy older (65-75y) and younger (18-28) men. The investigators will also explore how feeding affects muscle blood flow as this is important in the delivery of the nutrients we eat to the muscle where they are used.

The investigators plan to supplement the feed with arginine, a safe and widely found non-essential amino acid, to explore if this can improve muscle blood flow.


Description:

We will provide a 15g mixed essential amino acid feed or 4 x 3.75g.

There is sexual dimorphism thus initially we will just recruit males. Powering calculations dictate n=8 in each group.

We will use well established stable isotope tracer techniques (with 13C6 Phenylalanine) to measure muscle protein synthesis and breakdown by Gas Chromatography - combustion - isotope ratio mass spectroscopy.

We will measure leg blood flow by phase shift Doppler and muscle microvascular flow by contrast enhanced ultrasound.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date January 2014
Est. primary completion date January 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- age 65-75 or 18-28

Exclusion Criteria:

- BMI >30

- Diabetes

- Beta blocker or steroid use

- Established cerebrovascular, peripheral vascular or ischaemic heart disease.

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Old Age (Focus; Not a Recognized Condition)

Intervention

Dietary Supplement:
15g EAA bolus
Oral; in aqueous solution
4 x 3.75g Mixed EAA Pulses
Oral; in aqueous solution
15g EAA Bolus supplemented with 3g Arginine
Oral; in aqueous solution

Locations

Country Name City State
United Kingdom University of Nottingham School of Graduate Entry Medicine and Health Derby

Sponsors (1)

Lead Sponsor Collaborator
University of Nottingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Muscle Protein Synthesis (FSR, fractional synthetic rate, %/hr) We measure FSR when fasted and again 0-90, 90-180 and 180-240 post feed. Across 6hr study No
Secondary Muscle Protein Breakdown (MPB) MBP is measured during fasting and 0-90, 90-180 and 180-240mins post feed. Across 6hr study No
Secondary Whole leg blood flow We measure common femoral blood flow by doppler ultrasound when fasted and again 0-90, 90-180 and 180-240 post feed. Across a 6hr study No
Secondary Muscle Microvascular Blood flow We measure muscle microvascular flow using contrast enhanced ultrasound when fasted and again 0-90, 90-180 and 180-240 post feed. Across a 6hr study No